Tacklng the EML4/ALK Fusion Oncogenes in Murine Models.

被引：0
|
作者：
Hawes, J. [1 ]
Vilimas, T. [1 ]
Collins, K. [1 ]
Kozlov, S. [1 ]
机构：
[1] SAIC Frederick Inc, CAPR, FNLCR, Frederick, MD 21702 USA
来源：
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL | 2015年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
A-2007
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [31] A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review
    Yang, Shuzhe
    Bai, Zhongyuan
    Zhao, Qi
    Wang, Yajing
    Xi, Yanfeng
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [32] Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors
    Zhao, Peng
    Peng, Ling
    Wu, Wei
    Zheng, Yi
    Jiang, Weiqin
    Zhang, Hangyu
    Tong, Zhou
    Liu, Lulu
    Ma, Ruobing
    Wang, Liping
    Yao, Ming
    Wang, Kai
    Fang, Weijia
    Wu, Liming
    ONCOLOGIST, 2019, 24 (04): : 449 - 454
  • [33] Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors
    Waliany, Sarah
    Hung, Yin P.
    Abu Rous, Fawzi
    Do, Andrew
    Peterson, Jennifer
    Meservey, Caitlin
    Digumarthy, Subba R.
    Gadgeel, Shirish M.
    Lin, Jessica J.
    Meadori, Catherine B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E33
  • [34] The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
    E Normant
    G Paez
    K A West
    A R Lim
    K L Slocum
    C Tunkey
    J McDougall
    A A Wylie
    K Robison
    K Caliri
    V J Palombella
    C C Fritz
    Oncogene, 2011, 30 : 2581 - 2586
  • [35] Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
    J Tanizaki
    I Okamoto
    K Takezawa
    K Sakai
    K Azuma
    K Kuwata
    H Yamaguchi
    E Hatashita
    K Nishio
    P A Janne
    K Nakagawa
    British Journal of Cancer, 2012, 106 : 763 - 767
  • [36] New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
    Villa, Matteo
    Malighetti, Federica
    Sala, Elisa
    Sharma, Geeta G.
    Arosio, Giulia
    Gemelli, Maria
    Manfroni, Chiara
    Fontana, Diletta
    Cordani, Nicoletta
    Meneveri, Raffaella
    Zambon, Alfonso
    Piazza, Rocco
    Pagni, Fabio
    Cortinovis, Diego
    Mologni, Luca
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [37] EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
    Thomas Huang
    Brigitte J. Engelmann
    Rachael M. Morgan
    Kimberly J. Absher
    Jill M. Kolesar
    John L. Villano
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 965 - 968
  • [38] New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
    Matteo Villa
    Federica Malighetti
    Elisa Sala
    Geeta G. Sharma
    Giulia Arosio
    Maria Gemelli
    Chiara Manfroni
    Diletta Fontana
    Nicoletta Cordani
    Raffaella Meneveri
    Alfonso Zambon
    Rocco Piazza
    Fabio Pagni
    Diego Cortinovis
    Luca Mologni
    npj Precision Oncology, 8
  • [39] Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma
    Jiang, Liqun
    Chen, Suping
    Stinnett, Victoria
    Haley, Lisa
    Morsberger, Laura
    Shane, Alison
    Hardy, Melanie
    Smith, Kirstin
    Gocke, Christopher D.
    Lin, Ming-Tseh
    Zhou, Ying S.
    CANCER GENETICS, 2021, 258 : 18 - 22
  • [40] Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma
    Trombetta, Domenico
    Parente, Paola
    Latiano, Tiziana Pia
    Fabrizio, Federico Pio
    Muscarella, Lucia Anna
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 71 : 92 - 94
12345